Holger Nuckel

Bochum, NW 44787, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias.

Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias.

Journal: Journal of cancer research and clinical oncology
Published: June 23, 2025

Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial.

Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial.

Journal: Cancer medicine
Published: June 02, 2025

Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma.

Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma.

Journal: Cancers
Published: October 13, 2020

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Journal: Annals of hematology
Published: November 25, 2018

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Journal: Journal of cancer research and clinical oncology
Published: March 20, 2018

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.

Journal: Cancer
Published: June 21, 2016

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: October 13, 2015

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Journal: Haematologica
Published: August 02, 2014

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 12, 2014

Simple methods for the detection of HLA-G variants in coding and non-coding regions.

Simple methods for the detection of HLA-G variants in coding and non-coding regions.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 06, 2012

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

Journal: Therapeutic advances in neurological disorders
Published: March 22, 2012

p53 protein expression in chronic lymphocytic leukemia.

p53 protein expression in chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: January 07, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026